Lazard Capital Markets

Lazard Capital Markets is a growth-oriented full service broker-dealer with a unique position in today's capital markets.

Our Institutional clients value our focused, action-oriented proprietary research, which is based on deep domain expertise in the Healthcare, Consumer, Energy, Technology and Transportation sectors.

Our Sales and Trading professionals have long-standing relationships with over 600 institutional accounts, and, with an average of 15 years of experience, have an intimate knowledge of our clients' investment objectives. Finally, our relationship with Lazard, an international investment bank, which operates in 39 cities across 21 countries, provides us with unparalleled global connections.

The distinctive combination of our experience, focus, global reach, and thought leadership provides clients with an unparalleled resource: Lazard Capital Markets.

Lazard Capital Markets Daily Wednesday, November 19, 2008 CRM: Salesforce.com update and preview of 3Q results; lowering target to $45 from $56 on multiple contraction; BUY APP: When, not if; BUY DECK: Market not rational; BUY IMGN: Management dinner confirms potential of antibody-drug conjugate platform technology; BUY MASI: Our confidence in Hemoglobin increases; we would be buyers before the likely late 1Q09 rollout; BUY DNA: Management highlights T-DM1, Avastin adjuvant and Tarceva maintenance opportunity at LCM conference; BUY ABMD: Principal investigator discusses PROTECT II; BUY FRX: Takeaways from management dinner; BUY BEC: Dinner with management; BUY APPY: Update on clinical trial and 10-Q filing; BUY MFE: Updating model to reflect closure of the Secure Computing acquisition; BUY VRNM: Reorganization not indicative of issues with core business, BP negotiations remain on track; BUY SKS: Not as dire as stock reflects, but then what is? HOLD Highlights from our expert panel discussion on epilepsy SCUR: Dropping coverage due to acquisition by McAfee 2008 LCM Healthcare Conference: Takeaways from HCV panel and ITMN management dinner VFC: Well positioned to sail through stiff headwinds; HOLD AMLN: Liraglutide panel delay; next steps for exenatide LAR; BUY ISRG: Intuitive remains our top pick after our healthcare conference; stock looks very inexpensive; BUY

Terms and Conditions of Use

Member FINRA / SIPC